NUVECTIS PHARMA, INC.

(NASDAQ: NVCT)

 

 

 

Press Releases

14
Nov
2024
NXP800 demonstrated single agent activity New dosing schedule successfully minimized thrombocytopenia Fort Lee, NJ, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mu...
5
Nov
2024
Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancersNXP900 Phase 1a dose escalation study progressing as planned, 4 escalation cohorts completed with no DLTs, dose escalation continues FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical c...
First | Previous | Next  | Last

SEC Filings

First   Previous   Next   Last

Stock Information

$5.07
$-0.07|-1.36%
Bid:$4.83x100 Ask:$5.25x800
11/20/2024 4:03 PMET Volume:153,802
|Nasdaq|DELAYED PRICE
Last
$5.07
$Chg
$-0.07
Open
$5.09
High
$5.36
MarketCap
$97.957 M
Bid
$4.83
Bid Size
100
Year High
$12.10
PB Ratio
9.04
EPS
$-1.48
Volume
153,802
% Chg
-1.36%
Prev. Close
$5.14
Low
$4.81
Shares
19,320,973
Ask
$5.25
Ask Size
800
Year Low
$4.75
PE Ratio
-
Exchange
Nasdaq
Nov 20, 2024 4:03 PM ET

Governance